CA2356548A1 - Brainiac-5 humains - Google Patents

Brainiac-5 humains Download PDF

Info

Publication number
CA2356548A1
CA2356548A1 CA002356548A CA2356548A CA2356548A1 CA 2356548 A1 CA2356548 A1 CA 2356548A1 CA 002356548 A CA002356548 A CA 002356548A CA 2356548 A CA2356548 A CA 2356548A CA 2356548 A1 CA2356548 A1 CA 2356548A1
Authority
CA
Canada
Prior art keywords
polypeptide
brainiac
amino acid
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002356548A
Other languages
English (en)
Inventor
Paul E. Young
Steven M. Ruben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2356548A1 publication Critical patent/CA2356548A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de nouveaux polypeptides Brainiac-5 qui font partie de la famille des Brainiac. L'invention concerne, en particulier, des molécules d'acide nucléique isolées codant les polypeptides Brainiac-5 humains ; ainsi que des vecteurs, des cellules hôtes et des procédés de recombinaison permettant de produire ces derniers ; des procédés de criblage permettant d'identifier des agonistes et des antagonistes des activités de Brainiac-5 ; des procédés de diagnostic permettant de détecter des affections du système immunitaire et du système nerveux et des procédés thérapeutiques permettant de traiter, de prévenir et/ou de diagnostiquer les affections du système immunitaire et du système nerveux.
CA002356548A 1998-12-23 1999-12-20 Brainiac-5 humains Abandoned CA2356548A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11380498P 1998-12-23 1998-12-23
US60/113,804 1998-12-23
PCT/US1999/030452 WO2000039136A2 (fr) 1998-12-23 1999-12-20 Brainiac-5 humains

Publications (1)

Publication Number Publication Date
CA2356548A1 true CA2356548A1 (fr) 2000-07-06

Family

ID=22351630

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002356548A Abandoned CA2356548A1 (fr) 1998-12-23 1999-12-20 Brainiac-5 humains

Country Status (5)

Country Link
EP (1) EP1140120A4 (fr)
JP (1) JP2002533109A (fr)
AU (1) AU2202100A (fr)
CA (1) CA2356548A1 (fr)
WO (1) WO2000039136A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100543857B1 (ko) * 1999-09-01 2006-01-23 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제
WO2011082345A2 (fr) 2009-12-30 2011-07-07 Brigham Young University Compositions et procédés de gestion du cancer à l'aide d'anticorps de liaison aux enzymes des voies de récupération nucléotidique et à leurs complexes
CN114933646A (zh) * 2022-06-22 2022-08-23 南通市第一老年病医院(上海大学附属南通医院、南通市第六人民医院、南通市肺科医院) Smagp蛋白多肽构建及其抗脂肪性肝病活性的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4885297A (en) * 1996-11-13 1998-06-03 Protegene Inc. Human proteins having transmembrane domains and DNAs encoding these prot eins
EP0970214A1 (fr) * 1997-03-28 2000-01-12 Human Genome Sciences, Inc. Facteur de croissance derive du muscle humain - proteine cardiaque et pancreatique (capp) et gene associe
CA2314379A1 (fr) * 1997-12-18 1999-06-24 Human Genome Sciences, Inc. Dendriac et brainiac-3 humains
KR100543857B1 (ko) * 1999-09-01 2006-01-23 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제

Also Published As

Publication number Publication date
AU2202100A (en) 2000-07-31
JP2002533109A (ja) 2002-10-08
WO2000039136A2 (fr) 2000-07-06
EP1140120A4 (fr) 2003-05-07
WO2000039136A3 (fr) 2000-11-02
EP1140120A2 (fr) 2001-10-10

Similar Documents

Publication Publication Date Title
US7638603B2 (en) Antibodies against interleukin 17 receptor-like protein
US7776560B2 (en) Human tumor necrosis factor receptor TR9 antibody
US6689607B2 (en) Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
CA2363024A1 (fr) Proteine de type recteur de l'interleukine 17
US20020187526A1 (en) Neutrokine-alpha binding proteins and methods based thereon
US6503184B1 (en) Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
JP2010252803A (ja) ヒトエンドカインαおよび使用方法
US20030144191A1 (en) Polynucleotide encoding a novel TRP channel family member, TRP-PLIK2, and splice variants thereof
US8133734B2 (en) Kit comprising an antibody to interleukin 17 receptor-like protein
JP2004500810A (ja) Ｉｌ−６様ポリヌクレオチド、ポリペプチド、および抗体
WO2002066606A2 (fr) Polynucleotides codant une nouvelle sous unite alpha du recepteur de glycine exprimee dans le tractus gastro-intestinal, hgra4, variant d'epissage de ce dernier
WO2000050459A1 (fr) Proteines tr11, tr11sv1, et tr11sv2 du type recepteur tnf humain
US20030092017A1 (en) Polynucleotide encoding a novel immunoglobulin superfamily member, APEX4, and variants and splice variants thereof
CA2356548A1 (fr) Brainiac-5 humains
EP1187842B1 (fr) Protéine de fusion entre Fc et TR10, RECEPTEUR DE FACTEUR DE NECROSE TUMORALE HUMAIN
WO2000056862A1 (fr) Recepteur tr9 humain de facteurs de necrose des tumeurs
US20050090436A1 (en) Human tumor necrosis factor receptors TR21 and TR22
AU6102500A (en) Human tumor necrosis factor receptors tr13 and tr14
CA2422642A1 (fr) Recepteur hpraj70 de la proteine g specifique de la prostate humaine
EP1361883A2 (fr) Polynucleotide codant une sous-unite beta de canal potassique de type humain, k+b tam6, a forte expression dans l'intestin grele
AU2002306583A1 (en) Polynucleotide encoding a novel human potassium channel beta-subunit, K+betaM6, expressed highly in the small intestine
AU2002306796A1 (en) Polynucleotide encoding a novel immunoglobulin superfamily member, APEX4, and variants and splice variants thereof

Legal Events

Date Code Title Description
FZDE Dead